Previous Close | 108.43 |
Open | 111.81 |
Bid | 106.41 x 800 |
Ask | 112.25 x 800 |
Day's Range | 110.58 - 112.20 |
52 Week Range | 82.82 - 122.16 |
Volume | |
Avg. Volume | 1,476,990 |
Market Cap | 255.587B |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | 36.93 |
EPS (TTM) | 3.04 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.57 (1.48%) |
Ex-Dividend Date | Mar 25, 2022 |
1y Target Est | 130.93 |
Camp Huronda, home of Diabetes Canada's camp for children and youth living with type 1 diabetes and one of nine camps established under the D-Camps banner, is opening its doors to youth, families, and staff for the first time in two years. Diabetes Canada's Camps (D-Camps) strive to foster lifelong connections and provide exceptional programming for kids living with type 1 diabetes in a medically supervised environment.
Bagsværd, Denmark, 20 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.